Business
Nutriband Inc. Signs Exclusive Distribution Agreement With Oran Textiles for Cifra Reusable V-Block Coated Facemasks
ORLANDO, Fla., Sept. 15, 2020 /PRNewswire/ -- Nutriband Inc. (OTCQB: NTRB), announced that it has agreed terms with Irish based Oran Textiles Ltd. for the US
About this update from Nutriband Inc.
[{"type":"text","content":"ORLANDO, Fla., Sept. 15, 2020 /PRNewswire/ -- Nutriband Inc. (OTCQB: NTRB), announced that it has agreed terms with Irish based Oran Textiles Ltd. for the US and Korean distribution rights for Oran Textiles V-block coated facemasks. The masks, are a marriage of Italian based Cifra's Warpmask technology with HEIQ V-Block (Viroblock) technology.\n\nHeiQ's V-Block technology shown strong antimicrobial efficacy demonstrated by ISO 20743 and ISO 18184 tests. \nHeiQ's V-Block technology is a patent pending combination of advanced silver and vesicle booster technology.\nHEIQ V-BLOCK NPJ03 received positive results against SARS-CoV-2 in laboratory testing at the Doherty Institute for infection and immunity in Melbourne, Australia. The study has not been approved by the FDA nor has the company sought FDA approval for the masks at this time.\nThis mask is patented and fully engineered by Cifra Textiles.\nAbout Nutriband Inc.The Company is primarily engaged in the development of a portfolio of transdermal pharmaceutical products. Its lead product under development is its abuse deterrent fentanyl transdermal system, AVERSA, which the Company is developing to provide clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy combined with properties designed to help combat the opioid crisis by deterring the abuse and misuse of fentanyl patches.\nThe Company's website is www.nutriband.com and 4P's website is www.4PTherapeutics.com. Any material contained in or derived from the Company's or 4P's websites or any other website is not part of this press release.\nAbout Our Forward-Looking StatementsCertain statements contained in this press release, including, without limitation, statements containing the words \"believes,\" \"anticipates,\" \"expects\" and words of similar import, constitute \"forward-looking statements\" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve both known and unknown risks and uncertainties. The Company's actual results may differ materially from those anticipated in its forward-looking statements as a result of a number of factors, including those including the Company's ability to develop its proposed abuse deterrent fentanyl transdermal system and other propo...